ClinicalTrials.gg
CompletedNCT05810597Updated Oct 15, 2024Results posted

A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices

A Phase 1 interventional study of Tirzepatide and Single Dose Pen in Healthy, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices. The study will also evaluate the safety and tolerability of tirzepatide and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately 14 weeks, including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males or non-pregnant females as determined by medical history, physical examination, and other screening procedures
  • (BMI) between 18.5 and 30.0 kilograms per meter squared (kg/m²), inclusive, at screening
  • Have blood pressure, pulse rate, blood and urine laboratory test results that are acceptable for the study
  • Are agreeable to receiving study treatment by injections under the skin
  • Are agreeable to following study requirements

Exclusion criteria

Exclusion Criteria:

  • Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate, or could interfere with understanding the results of the study
  • Smoke more than the equivalent of 10 cigarettes per day
  • Is a known user of drugs of abuse
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Sequence 1: Tirzepatide by Single Dose Pen (SDP)/ Multi-use Prefilled Pen (MUPFP)

    Participants received a single dose of 5 milligrams (mg) tirzepatide administered subcutaneously (SC) via an SDP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 2. There was a washout period of at least 35 days between tirzepatide dose administrations.

    Drug: Tirzepatide · Device: Single Dose Pen · Device: Multi-use Prefilled Pen

  • Experimental
    Sequence 2: Tirzepatide by MUPFP / SDP

    Participants received a single dose of 5 mg tirzepatide administered SC via a MUPFP in Period 1 followed by a single dose of 5 mg tirzepatide administered SC via an SDP in Period 2. There was a washout period of at least 35 days between tirzepatide dose administrations.

    Drug: Tirzepatide · Device: Single Dose Pen · Device: Multi-use Prefilled Pen

Interventions

  • Administered SC

    Also known as: LY3298176

  • DeviceSingle Dose Pen

    Used to administer tirzepatide SC

  • DeviceMulti-use Prefilled Pen

    Used to administer tirzepatide SC

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide

    PK: Cmax of Tirzepatide

    Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide

    PK: AUC(0-t) of Tirzepatide

    Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.

  3. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide

    PK: AUC(0-∞) of Tirzepatide

    Time frame: Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.

07

Results

Posted Oct 15, 2024

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDP
Started3431
Received at least 1 dose of study drug3431
Completed3131
Not completed30
Withdrew: Adverse event20
Withdrew: Physician decision10
Period 2
Participant flow — Period 2
MilestoneSequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDP
Started3131
Received at least 1 dose of study drug3131
Completed3131
Not completed00

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide

PK: Cmax of Tirzepatide

Time frame:
Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide
nanograms per milliliter (ng/mL)Tirzepatide (SDP)Tirzepatide (MUPFP)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Tirzepatide647 ± 31524 ± 27
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide

PK: AUC(0-t) of Tirzepatide

Time frame:
Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
Reported as:
Geometric mean · nanogram *hour per milliliter (ng*h/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide
nanogram *hour per milliliter (ng*h/mL)Tirzepatide (SDP)Tirzepatide (MUPFP)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Time t, Where t is the Last Time Point With a Measurable Concentration (AUC[0-t]) of Tirzepatide124000 ± 23118000 ± 22
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide

PK: AUC(0-∞) of Tirzepatide

Time frame:
Predose, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 336, and 480 hours post Day 1 dose and on Day 36 of each study period.
Reported as:
Geometric mean · ng*h/mL
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide
ng*h/mLTirzepatide (SDP)Tirzepatide (MUPFP)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Tirzepatide126000 ± 22119000 ± 22

Adverse events

Collected over Baseline Up To 82 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tirzepatide (SDP)0/65 (0%)0/65 (0%)38/65 (58.5%)
Tirzepatide (MUPFP)0/62 (0%)0/62 (0%)28/62 (45.2%)
Most frequent other events
Most frequent other events
EventTirzepatide (SDP)Tirzepatide (MUPFP)
Decreased appetiteMetabolism and nutrition disorders17/6514/62
NauseaGastrointestinal disorders16/6514/62
DyspepsiaGastrointestinal disorders10/657/62
HeadacheNervous system disorders10/655/62
VomitingGastrointestinal disorders9/657/62
PainGeneral disorders4/656/62
DiarrhoeaGastrointestinal disorders3/654/62

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Sequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDPTotal
Mean41.10 ± 13.3241.10 ± 14.5241.10 ± 13.79
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDPTotal
Female181735
Male161430
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDPTotal
Hispanic or Latino161733
Not Hispanic or Latino181432
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDPTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American426
White292958
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Sequence 1: Tirzepatide by SDP / MUPFPSequence 2: Tirzepatide by MUPFP / SDPTotal
United States343165
08

Study locations

3 sites
  • Qps-Mra, Llc
    South Miami, Florida 33143, United States
  • ICON Early Phase Services
    San Antonio, Texas 78209, United States
  • ICON
    Salt Lake City, Utah 84124, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jul 2023, 3 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2023
First posted
Apr 12, 2023
StartActual
Apr 3, 2023
Primary completionActual
Jul 17, 2023
CompletionActual
Jul 17, 2023
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05810597
Responsible party
Sponsor
First posted
Apr 12, 2023
Start date
Apr 3, 2023
Primary completion
Jul 17, 2023
Completion
Jul 17, 2023
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion